Assistant Professor
Division of Biostatistics and Population HealthDepartment of Biomedical Informatics
Mohamed.Elsaid@osumc.edu
Background
Mohamed I. Elsaid, Ph.D., MPH, ALM, is an Assistant Professor in the Division of Biostatistics and Population Health within the Department of Biomedical Informatics at The Ohio State University College of Medicine. He is also a member of the Cancer Control Program at The Ohio State University Comprehensive Cancer Center—The James Cancer Hospital and Solove Research Institute. Dr. Elsaid brings extensive expertise in causal inference methodologies, precision medicine, comparative effectiveness research, and secondary data analyses. His research utilizes large databases, high-dimensional data, population-based cohorts, nationally representative surveys, and electronic medical records to develop predictive and inferential-based statistical models. As the Principal Investigator of the Causal Inference in Hepatology and Oncology (CIHO) Lab, Dr. Elsaid directs an innovative research program dedicated to investigating the complex interplay between liver diseases, cancer prevention, and health disparities through advanced causal inference methodologies. His work endeavors to elucidate the causal pathways in liver disease and cancer—particularly hepatocellular carcinoma (HCC)—to address the disproportionate burden of these diseases across diverse populations. Dr. Elsaid leverages novel multi-omics biomarkers in conjunction with phenotypic and environmental exposure data—including social determinants of health—to develop and evaluate pragmatic, personalized cancer prevention interventions. By transforming complex clinical data into actionable insights, he aims to inform public health policies and clinical practices, ultimately promoting equitable health outcomes for all communities.A central aspect of Dr. Elsaid's research is addressing health disparities. He investigates the social, economic, and environmental factors that contribute to inequitable health outcomes in liver disease and cancer. Through this perspective, he aims to promote equitable cancer prevention by identifying modifiable risk factors and interventions that are accessible and effective across diverse populations. Dr. Elsaid facilitates interdisciplinary collaboration, bridging the gaps between epidemiology, hepatology, oncology, biostatistics, and social sciences to encourage comprehensive research approaches. His commitment extends to educating and mentoring the next generation of researchers, emphasizing the significance of health equity and the application of advanced statistical methods to real-world clinical challenges. In addition to his primary research focus, Dr. Elsaid is actively engaged in developing causal inference-based methodologies to assess bias in clinical trials and observational studies to enhance the validity and reliability of research findings. He currently serves as the Biostatistics and Epidemiology Editor of Gastro Hep Advances, an official peer-reviewed journal of the American Gastroenterological Association (AGA).
Selected Publications
Elsaid MI, Li N, Firkins SA, Rustgi VK, Paskett ED, Acharya C, Reddy KR, Chiang CW, Mumtaz K. Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Aliment Pharmacol Ther. 2024 Mar 27. doi: 10.1111/apt.17925. Epub ahead of print. PMID: 38538967.
Elsaid MI, Bridges JFP, Mumtaz K, Li N, Sobotka L, Rustgi VK, Paskett ED. The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease. PLoS One. 2024 Mar 15;19(3):e0299836. doi: 10.1371/journal.pone.0299836. PMID: 38489287.
Chen JC, Elsaid MI, Handley D, Plascak JJ, Andersen BL, Carson WE, Pawlik TM, Fareed N, Obeng-Gyasi S. Association Between Neighborhood Opportunity, Allostatic Load, and All-Cause Mortality in Patients With Breast Cancer. J Clin Oncol. 2024 Feb 16:JCO2300907. doi: 10.1200/JCO.23.00907. Epub ahead of print. PMID: 38364197.
Chen JC, Handley D, Elsaid MI, Fisher JL, Plascak JJ, Anderson L, Tsung C, Beane J, Pawlik TM, Obeng-Gyasi S. Persistent Neighborhood Poverty and Breast Cancer Outcomes. JAMA Netw Open. 2024 Aug 1;7(8):e2427755. doi: 10.1001/jamanetworkopen.2024.27755. PMID: 39207755.
Elsaid MI, Zhang X, Schuster ALR, Plascak JJ, DeGraffinreid C, Paskett ED. The impact of socioeconomic status on changes in cancer prevention behavior during the COVID-19 pandemic. PLoS One. 2023 Jun 30;18(6):e0287730. doi: 10.1371/journal.pone.0287730. PMID: 37390051; PMCID: PMC10313075.
Zhang X, Elsaid MI, DeGraffinreid C, Champion VL, Paskett ED; Impact of COVID-19 on Behaviors across the Cancer Control Continuum in Ohio group. Impact of the COVID-19 Pandemic on Cancer Screening Delays. J Clin Oncol. 2023 Jun 10;41(17):3194-3202. doi: 10.1200/JCO.22.01704. Epub 2023 Feb 3. PMID: 36735899; PMCID: PMC10256430.
Rustgi VK, Duff SB, Elsaid MI. Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease. J Med Econ. 2022 Jan-Dec;25(1):347-355. doi: 10.1080/13696998.2022.2026702. PMID: 35034553.
Elsaid MI, Bridges JFP, Li N, Rustgi VK. Metabolic Syndrome Severity Predicts Mortality in Nonalcoholic Fatty Liver Disease. Gastro Hep Adv. 2022 Apr 8;1(3):445-456. doi: 10.1016/j.gastha.2022.02.002. PMID: 39131673; PMCID: PMC11308509.
Rustgi VK, Li Y, Gupta K, Minacapelli CD, Bhurwal A, Catalano C, Elsaid MI. Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity. Gastroenterology. 2021 Jul;161(1):171-184.e10. doi: 10.1053/j.gastro.2021.03.021. Epub 2021 Mar 18. PMID: 33744305.
Elsaid MI, Rustgi VK. Epidemiology of Hepatic Encephalopathy. Clin Liver Dis. 2020 May;24(2):157-174. doi: 10.1016/j.cld.2020.01.001. Epub 2020 Mar 2. PMID: 32245524.
Education and Training
Post-Doc, The Ohio State University, 2021
PhD, Rutgers the State University of New Jersey, 2020
MPH, New York Medical College, 2014
ALM, Harvard University, 2013
Location
340F Lincoln Tower
1800 Cannon Drive
Columbus, OH 43210